{
    "id": 471,
    "fullName": "ESR1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type ESR1 indicates that no mutation has been detected within the ESR1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/02/2014",
    "updateDate": "04/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21219,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring wild-type ESR1 in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21218,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring wild-type ESR1 in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3640,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bazedoxifene inhibited human breast cancer cells expressing ESR1 wild-type in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21217,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring wild-type ESR1 in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3654,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited tumor growth in patient derived breast cancer xenografts with wild-type ESR1 (PMID: 25991817).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3639,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited human breast cancer cells expressing ESR1 wild-type in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3641,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pipendoxifene inhibited human breast cancer cells expressing ESR1 wild-type in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 3207,
                "therapyName": "pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21227,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) treatment resulted in estrogen receptor degradation and inhibition of ER signaling, led to inhibition of growth of both CDK4/6 inhibitor-sensitive and CDK4/6 inhibitor-resistant breast cancer cell lines harboring wild-type ESR1 in culture, and tumor growth inhibition in patient-derived xenograft models (PMID: 31852484).",
            "molecularProfile": {
                "id": 534,
                "profileName": "ESR1 wild-type"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21230,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) did not inhibit tumor growth in a xenograft (PDX) model of breast cancer harboring PIK3CA E88Q and wild-type ESR1 that was derived from a patient treated with a combination of Femara (letrozole) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35879,
                "profileName": "ESR1 wild-type PIK3CA R88Q"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21231,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Piqray (Alpelisib) treatment resulted in significant tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E88Q and wild-type ESR1 that was derived from a patient treated with a combination of Femara (letrozole) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35879,
                "profileName": "ESR1 wild-type PIK3CA R88Q"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21233,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Piqray (Alpelisib) and Elacestrant (RAD1901) combination treatment resulted in near complete tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E88Q and wild-type ESR1 that was derived from a patient treated with a combination of Femara (letrozole) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35879,
                "profileName": "ESR1 wild-type PIK3CA R88Q"
            },
            "therapy": {
                "id": 9642,
                "therapyName": "Alpelisib + Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21232,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) treatment resulted in significant tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E88Q and wild-type ESR1 that was derived from a patient treated with a combination of Femara (letrozole) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35879,
                "profileName": "ESR1 wild-type PIK3CA R88Q"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 534,
            "profileName": "ESR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35879,
            "profileName": "ESR1 wild-type PIK3CA R88Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}